CAMBRIDGE, Mass. August 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Canaccord...
– Leading sleep expert and former president of American Academy of Sleep Medicine to take on a greater role in day-to-day operations of the company CAMBRIDGE, Mass. July 27, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for...
CAMBRIDGE, Mass. July 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Ladenburg...
– AD128 is a drug combination under development by Apnimed for the treatment of Obstructive Sleep Apnea – – Phase 2 data from Apnimed’s most advanced drug candidate for Obstructive Sleep Apnea, AD109, anticipated in 2ndquarter of this year – CAMBRIDGE, Mass. May 17,...
CAMBRIDGE, Mass. April 12, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the 20th Annual...
